A:

While biotechnology and pharmaceutical companies both produce medicine, biotechnology companies' medicines have a biological basis, and pharmaceutical companies' medicines have a chemical basis. Biotechnology companies use live organisms or their products, such as bacteria or enzymes, to manufacture their drugs. Conversely, pharmaceutical companies use only chemical – and generally artificial – materials to create drugs.

Biotechnology also has more applications than pharmaceutical companies. For example, biotechnology companies have developed versions of crops without specific food allergens, crops that require fewer pesticides and crops with a more complete nutrient profile. While there is some overlap between biotechnology and pharmaceutical companies in terms of research, manufacturing and distributing drugs, biotechnology's scope is much greater.

There is also a substantial difference in operating costs, especially the cost of research and development. Biotechnology companies have much higher costs due to their focus on research and development (as opposed to manufacturing with pharmaceutical companies) and the length of time and difficulty in testing and creating new products.

The discrepancy in the cost and length of time required to manufacture a new product has led to biotechnology products holding their patents for much longer than pharmaceutical companies. Where pharmaceutical companies generally hold the exclusive rights to manufacture and distribute their drugs for five years, biotechnology companies have their patents for 12 years.

All of this leads to very volatile profits for biotechnology companies. Many operate at a loss for many years until a highly profitable substance is manufactured, when their profits can be even greater than pharmaceutical companies. Conversely, pharmaceutical companies' profits, and therefore their stock prices, tend to fluctuate less.

RELATED FAQS
  1. Why would a growth investor purchase shares of companies in the drug sector?

    Learn why growth investors looking to beat the market gravitate toward the drugs sector, particularly the newer, high-tech ... Read Answer >>
  2. What annual return could an investor expect on average from the drug sector?

    Learn which annual average returns the drugs manufacturing sector and its industries can generate for investors based on ... Read Answer >>
  3. Why should an investor include an allocation to the drugs sector in their portfolio?

    Learn why investors should consider allocating assets to the drug sector as part of a diversified investment portfolio and ... Read Answer >>
  4. What options strategies are best suited for investing in the drugs sector?

    Learn how the covered call strategy works well with the pharmaceuticals segment of the drugs sector and how the long straddle ... Read Answer >>
  5. What percentage of a diversified portfolio should be invested in the drugs sector?

    Learn how to determine how much of a diversified portfolio should be devoted to the pharmaceutical and biotechnology segments ... Read Answer >>
  6. How does the risk of investing in the drugs sector compare to the broader market?

    Learn how the risk of investing in the drugs sector compares to the broader market and what steps investors take to mitigate ... Read Answer >>
Related Articles
  1. Investing

    IBB: iShares NASDAQ Biotechnology ETF

    Learn about the iShares Nasdaq Biotechnology exchange-traded fund, which offers one of the most diversified ways of investing in the biotechnology sector.
  2. Investing

    A Quick Guide To Healthcare ETFs

    The healthcare industry offers a broad variety of sector ETFs but it’s difficult to avoid exposure to pharmaceuticals and biotechnology .
  3. Investing

    Biotech ETF Investors are Still on the Sidelines

    Biotech ETFs are surging, but investors aren't taking the bait. Not yet, at least.
  4. Investing

    The Top 5 Biotechnology Mutual Funds for 2016

    Explore detailed analyses of the top biotechnology-related mutual funds for 2016, and learn about the characteristics of these funds poised for a rebound.
  5. Financial Advisor

    Investing In Biotech: Is It Worth The Risk?

    Investors shunned biotech after a weak start in 2014. Now that a comeback is in the works, should they reconsider?
  6. Investing

    (XBI, FBT, IBB) 3 Bond ETFs in the Biotech Sector

    Learn about the top biotechnology ETFs, such as the SPDR S&P Biotech ETF, the First Trust NYSE Arca Biotech ETF and the iShares Nasdaq Biotech ETF.
  7. Investing

    UBIO: ProShares UltraPro Nasdaq Biotech ETF

    Obtain information about an ETF offerings that provides leveraged exposure to the biotechnology industry, the ProShares UltraPro Nasdaq Biotech Fund.
  8. Investing

    A Primer On The Biotech Sector

    Investing in the biotech sector can involve both huge losses and major gains.
  9. Investing

    Key Financial Ratios to Analyze Biotech Companies (AMGN, GILD)

    Explore the rapidly growing biotechnology industry, and learn some of the key financial ratios investors use to analyze companies in the industry.
  10. Investing

    Active Traders Turn Bullish on Biotech

    The recent price activity of two key ETFs suggests that the biotech sector is poised for a comeback.
RELATED TERMS
  1. Biotechnology Industry ETF

    An exchange-traded fund that invests specifically in the rapidly ...
  2. Biotechnology

    The use of living organisms to make products or run processes. ...
  3. Pharmaceutical Industry ETF

    A sector-following fund that invests in developers and manufacturers ...
  4. Stock And Warrant Off-Balance Sheet R&D - SWORD

    A financing option developed to help biotechnology companies ...
  5. Intellectual Property Rights (Biotechnology)

    In health care, intellectual property rights give their owners ...
  6. Medical Patent

    A legal protection against market competition that a government ...
Hot Definitions
  1. Current Assets

    A balance sheet account that represents the value of all assets that can reasonably expected to be converted into cash within ...
  2. Tax Liability

    The total amount of tax that an entity is legally obligated to pay to an authority as the result of the occurrence of a taxable ...
  3. Preferred Stock

    A class of ownership in a corporation that has a higher claim on its assets and earnings than common stock. Preferred shares ...
  4. Net Profit Margin

    Net Margin is the ratio of net profits to revenues for a company or business segment - typically expressed as a percentage ...
  5. Gross Margin

    A company's total sales revenue minus its cost of goods sold, divided by the total sales revenue, expressed as a percentage. ...
  6. Current Ratio

    The current ratio is a liquidity ratio measuring a company's ability to pay short-term and long-term obligations, also known ...
Trading Center